Abstract
Praziquantel administered in a single oral dose of 30 mg kg-1 to subjects infected with Schistosoma haematobium produced minimal side effects and was more effective than established regimes of niridazole and metrifonate. Praziquantel should prove a major tool in schistosomiasis control programmes.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Humans
-
Isoquinolines / therapeutic use*
-
Niridazole / adverse effects
-
Niridazole / therapeutic use*
-
Praziquantel / adverse effects
-
Praziquantel / therapeutic use*
-
Random Allocation
-
Schistosoma haematobium / drug effects
-
Schistosomiasis / drug therapy*
-
Trichlorfon / adverse effects
-
Trichlorfon / therapeutic use*
Substances
-
Isoquinolines
-
Praziquantel
-
Trichlorfon
-
Niridazole